Homology Medicines, Inc. (FIXX) News

Homology Medicines, Inc. (FIXX): $6.81

-0.22 (-3.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter FIXX News Items

FIXX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FIXX News Highlights

  • For FIXX, its 30 day story count is now at 5.
  • Over the past 8 days, the trend for FIXX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about FIXX are GENE, RARE and VIVO.

Latest FIXX News From Around the Web

Below are the latest news stories about Homology Medicines Inc that investors may wish to consider to help them evaluate FIXX as an investment opportunity.

Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting

- Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations - BEDFORD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today two presentations highlighting clinical and preclinical data from the Company’s phenylketonuria (PKU) and MPS II (Hunter syndrome) in vivo gene therapy programs, respectively, at the virtual American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. “We continue to demonstrate the breadth of our growing pipeline with expanded focus on diseases of the central nervous system,” stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. “Our AAVHSC vectors have shown the ability to target peripher...

Yahoo | April 14, 2021

Homology Medicines promotes Tim Kelly to COO

Homology Medicines (FIXX) announces the promotion of Tim Kelly to chief operating officer from previously held role of the company's chief technical operating officer.The change in effective immediately.Prior to joining Homology Medicines, Kelly has held leadership positions at Shire (SHPG), Sarepta Therapeutics (SRPT), Biogen Idec and UCB S.A (UCBJF).Company statement, "Under...

Seeking Alpha | April 12, 2021

Why Homology Medicines Stock Is Sinking Today

Shares of Homology Medicines (NASDAQ: FIXX) were sinking 17.8% lower as of 12:01 p.m. EDT on Wednesday. The decline came after the company announced the pricing of its latest public stock offering. Biotech stocks usually fall after public stock offerings are announced.

Yahoo | April 7, 2021

Homology Medicines Announces Pricing of Public Offering of Common Stock

BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately $50.0 million, before deducting estimated offering expenses payable by Homology. Homology also granted the underwriter a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. All of the shares in the offering are to be sold by Homology. BTIG is the sole book-running manager for the offering. The offering is expected to close on or about April 9, 2021, subject to customary closing conditions. Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead ...

Yahoo | April 7, 2021

Homology Medicines Announces Proposed Public Offering of Common Stock

BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares in the proposed offering are to be sold by Homology. BTIG is the sole book-running manager for the offering. Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead gene therapy candidate, HMI-102, for the treatment of phenylketonuria (PKU) in adults through the ongoi...

Yahoo | April 6, 2021

Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates

Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 12, 2021

Earnings Preview: Homology Medicines (FIXX) Q4 Earnings Expected to Decline

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | March 4, 2021

Homology Medicines Regains Global Rights To Novartis Ophthalmology Program

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing technology platform for an ophthalmic target. Novartis had concluded the collaboration and licensing agreement with Homology announced in 2017 to pursue other opportunities in their pipeline. The company has generated in vivo data in two different eye targets. "AAVHSC vectors can edit the back of the eye, and we plan to share additional data from the ophthalmology program at a scientific meeting in May," said Arthur Tzianabos, President and CEO of Homology Medicines. Price Action: FIXX shares were trading 3.54% higher at $11.12, and NVS shares were up 0.8% at $86.61 in market trading hou...

Yahoo | March 1, 2021

Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform

- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - BEDFORD, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today it has regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize Homology’s proprietary nuclease-free gene editing technology platform for an ophthalmic target. Following a portfolio review, Novartis decided to conclude the collaboration and licensing agreement with Homology to pursue other opportunities in their pipeline. “Our nuclease-free gene editing platform is applicable across a broad range of genetic disorders, including ophthalmic diseases where we have generated positive in vi...

Yahoo | March 1, 2021

Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences

BEDFORD, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences: Cowen 41st Annual Health Care Conference Panel discussion: March 1 at 11:40 a.m. ET H.C. Wainwright Global Life Sciences Conference Fireside chat: Available on-demand March 9 at 7:00 a.m. ET CureMLD’s MLD Standards of Care Meeting Panel discussion, “Updates in MLD Clinical Therapies”: March 12 at 10:00 a.m. ET Oppenheimer & Co. 31st Annual Healthcare Conference Fireside chat: March 16 at 11:20 a.m. ET The webcast presentations from the H.C. Wainwright and Oppenheimer conferences will be accessible on Homology’s website in the Investors section, and the webcast replays will be available o...

Yahoo | February 25, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7781 seconds.